Pharmacotherapies for Post-Bariatric Weight Regain: Real-World Comparative Outcomes

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Objective: This study aimed to compare outcomes of treatment strategies for weight regain after bariatric surgery. Methods: This is a retrospective analysis of 207 individuals treated for post-bariatric weight regain at an academic center from January 1, 2014, through November 25, 2019. Percentage body weight loss was compared after 3, 6, 9, and 12 months of treatment among an intensive lifestyle modification (ILM) group, a non–glucagon-like-1 receptor agonist (GLP-1-RA)-based weight-loss pharmacotherapy (WLP) group, and a GLP-1-RA-based WLP group (the latter two groups in conjunction with ILM). Results: The percentage body weight loss was significantly different between groups after 3 months (1.4% vs. 2.2% vs. 4.5% [P < 0.001] for ILM, non–GLP-1-RA-based WLP, and GLP-1-RA-based WLP groups, respectively), 6 months (0.8% vs. 2.9% vs. 6.7% [P < 0.001]), and 9 months (−1.6% vs. 5.6% vs. 6.9% [P = 0.007]). There was a significant difference in the percentage of individuals achieving ≥5% weight loss after 3, 6, and 9 months, with most occurring in the GLP-1-RA-based WLP group. In a multiple regression analysis including bariatric surgery type, treatment group was the only significant predictor of percentage weight change. Conclusions: GLP-1-RA-based WLP therapies were found to be more effective for treating post-bariatric weight regain than non–GLP-1-RA-based WLP or ILM, regardless of surgery type.

Original languageEnglish (US)
Pages (from-to)829-836
Number of pages8
Issue number5
StatePublished - May 2021

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics


Dive into the research topics of 'Pharmacotherapies for Post-Bariatric Weight Regain: Real-World Comparative Outcomes'. Together they form a unique fingerprint.

Cite this